ATG16L1 and neoplasm: Livers from mice administered WT CRC organoids displayed extensive disease burden 6 weeks after inoculation, whereas a minority of mice (<40%) administered Atg16l1 KO CRC organoids presented with only occasional tumor foci (Fig. 2i and Supplementary Fig. 5b–e).